Sonoma Pharmaceuticals to Present at H.C. Wainwright BioConnect Virtual Conference January 10-13, 2022
05 Enero 2022 - 3:55PM
Business Wire
Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare
leader developing and producing stabilized hypochlorous acid (HOCl)
products for a wide range of applications, including wound care,
eye care, nasal care, oral care and dermatological conditions,
today announced that it will be featured as a presenting company at
the H.C. Wainwright BioConnect Conference. The conference is being
held on January 10-13, 2022 virtually.
Amy Trombly, CEO and Jerry Dvonch, CFO will provide an overview
of the Company’s business during the presentation.
If you are an institutional investor, and would like to listen
to the Company’s presentation, please click on the following link
(www.hcwevents.com/bioconnect) to register for the conference. Over
500 corporate presentations & panels are available on-demand
during January 10-13, 2022.
Event: H.C. Wainwright BioConnect Conference (Virtual
Conference) Date: January 10-13, 2022 Location: Virtual
Conference
In addition, the Company will furnish the presentation on a
current report on Form 8-K with the U.S. Securities and Exchange
Commission via EDGAR.
About Sonoma Pharmaceuticals, Inc.
Sonoma Pharmaceuticals is a global healthcare leader for
developing and producing stabilized hypochlorous acid (HOCl)
products for a wide range of applications, including wound care,
animal health care, eye care, nasal care, oral care, and
dermatological conditions. The company’s products reduce
infections, itch, pain, scarring and harmful inflammatory responses
in a safe and effective manner. In-vitro and clinical studies of
hypochlorous acid (HOCl) show it to have impressive antipruritic,
antimicrobial, antiviral and anti-inflammatory properties. Sonoma’s
stabilized HOCl immediately relieves itch and pain, kills pathogens
and breaks down biofilm, does not sting or irritate skin and
oxygenates the cells in the area treated assisting the body in its
natural healing process. The company’s products are sold either
directly or via partners in 54 countries worldwide and the company
actively seeks new distribution partners. The company’s principal
office is in Woodstock, Georgia, with manufacturing operations in
Latin America. European marketing and sales are headquartered in
Roermond, Netherlands. More information can be found at
www.sonomapharma.com. For partnership opportunities, please contact
busdev@sonomapharma.com.
About H.C. Wainwright & Co.
H.C. Wainwright is a full‐service investment bank dedicated to
providing corporate finance, strategic advisory and related
services to public and private companies across multiple sectors
and regions. H.C. Wainwright & Co. also provides research and
sales and trading services to institutional investors. According to
Sagient Research Systems, H.C. Wainwright’s team is ranked as the
#1 Placement Agent in terms of aggregate CMPO (confidentially
marketed public offering), RD (registered direct offering) and PIPE
(private investment in public equity) executed cumulatively since
1998. For more information visit H.C. Wainwright & Co. on the
web at www.hcwco.com
Forward-Looking Statements
Except for historical information herein, matters set forth in
this press release are forward-looking within the meaning of the
“safe harbor” provisions of the Private Securities Litigation
Reform Act of 1995, including statements about the commercial and
technology progress and future financial performance of Sonoma
Pharmaceuticals, Inc. and its subsidiaries (the “company”). These
forward-looking statements are identified by the use of words such
as “continue,” “believe,” “develop” and “expand,” among others.
Forward-looking statements in this press release are subject to
certain risks and uncertainties inherent in the company’s business
that could cause actual results to vary, including such risks that
regulatory clinical and guideline developments may change,
scientific data may not be sufficient to meet regulatory standards
or receipt of required regulatory clearances or approvals, clinical
results may not be replicated in actual patient settings,
protection offered by the company’s patents and patent applications
may be challenged, invalidated or circumvented by its competitors,
the available market for the company’s products will not be as
large as expected, the company’s products will not be able to
penetrate one or more targeted markets, revenues will not be
sufficient to meet the company’s cash needs, fund further
development, as well as uncertainties relative to the COVID-19
pandemic and economic development, varying product formulations and
a multitude of diverse regulatory and marketing requirements in
different countries and municipalities, and other risks detailed
from time to time in the company’s filings with the Securities and
Exchange Commission. The company disclaims any obligation to update
these forward-looking statements, except as required by law.
Sonoma Pharmaceuticals™ and Microcyn® are trademarks or
registered trademarks of Sonoma Pharmaceuticals, Inc. All other
trademarks and service marks are the property of their respective
owners.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220105006001/en/
Media and Investor Contact: Sonoma Pharmaceuticals, Inc.
ir@sonomapharma.com
Sonoma Pharmaceuticals (NASDAQ:SNOA)
Gráfica de Acción Histórica
De Ago 2024 a Sep 2024
Sonoma Pharmaceuticals (NASDAQ:SNOA)
Gráfica de Acción Histórica
De Sep 2023 a Sep 2024